Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Daxx, a death domain-associated protein, has been implicated in proapoptosis, antiapoptosis, and transcriptional regulation. Many factors known to play critically important roles in controlling apoptosis and gene transcription have been shown to associate with Daxx, including the Ser/Thr protein kinase
HIPK2
, promyelocytic leukemia protein, histone deacetylases, and the chromatin remodeling protein ATRX. Although it is clear that Daxx may exert multiple functions, the underlying mechanisms remain far from clear. Here, we show that Axin, originally identified for its scaffolding role to control beta-catenin levels in Wnt signaling, strongly associates with Daxx at endogenous levels. The Daxx/Axin complex formation is enhanced by UV irradiation. Axin tethers Daxx to the
tumor suppressor p53
, and cooperates with Daxx, but not DaxxDeltaAxin, which is unable to interact with Axin, to stimulate
HIPK2
-mediated Ser(46) phosphorylation and transcriptional activity of
p53
. Interestingly, Axin and Daxx seem to selectively activate p53 target genes, with strong activation of PUMA, but not p21 or Bax. Daxx-stimulated
p53
transcriptional activity was significantly diminished by small interfering RNA against Axin; Daxx fails to inhibit colony formation in Axin(-/-) cells. Moreover, UV-induced cell death was attenuated by the knockdown of Axin and Daxx. All these results show that Daxx cooperates with Axin to stimulate
p53
, and implicate a direct role for Axin,
HIPK2
, and
p53
in the proapoptotic function of Daxx. We have hence unraveled a novel aspect of
p53
activation and shed new light on the ultimate understanding of the Daxx protein, perhaps most pertinently, in relation to stress-induced cell death.
...
PMID:Daxx cooperates with the Axin/HIPK2/p53 complex to induce cell death. 1721 Jun 84
In response to DNA damage,
p53
induces either cell-cycle arrest or apoptosis by differential transcription of several target genes and through transcription-independent apoptotic functions.
p53
phosphorylation at Ser46 by
HIPK2
is one determinant of the outcome because it takes place only upon severe, nonrepairable DNA damage that irreversibly drives cells to apoptosis. Here, we show that
p53
represses its proapoptotic activator
HIPK2
via MDM2-mediated degradation, whereas a degradation-resistant
HIPK2
mutant has increased apoptotic activity. Upon cytostatic, nonsevere DNA damage, inhibition of
HIPK2
degradation is sufficient to induce p53Ser46 phosphorylation and apoptosis, converting growth-arresting stimuli to apoptotic ones. These findings establish
HIPK2
as an MDM2 target and support a model in which, upon nonsevere DNA damage,
p53
represses its own phosphorylation at Ser46 due to
HIPK2
degradation, supporting the notion that the cell-cycle-arresting functions of
p53
include active inhibition of the apoptotic ones.
...
PMID:MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis. 1738 56
Differentiation of hematopoietic stem and progenitor cells is an intricate process controlled in large part at the level of transcription. While some key megakaryocytic transcription factors have been identified, the complete network of megakaryocytic transcriptional control is poorly understood. Using global gene expression microarray analysis, Gene Ontology-based functional annotations, and a novel interlineage comparison with parallel, isogenic granulocytic cultures as a negative control, we closely examined the mRNA level of transcriptional regulators in megakaryocytes derived from human mobilized peripheral blood CD34(+) hematopoietic cells. This approach identified 199 differentially expressed transcription factors or transcriptional regulators. We identified and detailed the transcriptional kinetics of most known megakaryocytic transcription factors including GATA1, FLI1, and MAFG. Furthermore, many genes with transcription factor activity or transcription factor binding activity were identified in megakaryocytes that had not previously been associated with that lineage, including BTEB1, NR4A2, FOXO1A, MEF2C, HDAC5, VDR, and several genes associated with the
tumor suppressor p53
(
HIPK2
, FHL2, and TADA3L). Protein expression and nuclear localization were confirmed in megakaryocytic cells for four of the novel candidate megakaryocytic transcription factors: FHL2, MXD1, E2F3, and RFX5. In light of the hypothesis that transcription factors expressed in a particular differentiation program are important contributors to such a program, these data substantially expand our understanding of transcriptional regulation in megakaryocytic differentiation of stem and progenitor cells.
...
PMID:Gene Ontology-driven transcriptional analysis of CD34+ cell-initiated megakaryocytic cultures identifies new transcriptional regulators of megakaryopoiesis. 1825 2
Approximately 50% of sporadic human tumors harbor somatic mutations in the
p53
gene locus, while germ line mutations confer a high familial risk and are associated with Li-Fraumeni Syndrome patients. The
p53 tumor suppressor protein
is often referred to as the "guardian of the genome" since its response to DNA-damage or checkpoint failure gives rise to a series of anti-proliferative responses. One of the most important functions of
p53
is its ability to induce apoptosis, while disruption of this route can promote tumor progression and chemo resistance. Besides its ability to promote apoptosis through transcription dependent mechanisms,
p53
may also be able to activate apoptosis independent of transcriptional regulation. Therefore, to ensure normal cell growth,
p53
levels and activity are tightly regulated. Upon diverse forms of cellular stress the steady state levels and transcriptional activity of
p53
are considerably increased. The stabilization and activation of
p53
are a result of hindered inhibition by its negative regulators, e.g. Mdmx (also known as Mdm4) and Mdm2, while on the other hand activators such as
HIPK2
and DYRK2 enhance the
p53
response. The continually increasing understanding of the mechanisms of regulation of
p53
may provide the basis for new drug designs that could eventually lead to therapeutics to reactivate
p53
in cancers.
...
PMID:p53: a guide to apoptosis. 1833 91
The tumour suppressor
HIPK2
is an important regulator of cell death induced by DNA damage, but how its activity is regulated remains largely unclear. Here we demonstrate that
HIPK2
is an unstable protein that colocalizes and interacts with the E3 ubiquitin ligase Siah-1 in unstressed cells. Siah-1 knockdown increases
HIPK2
stability and steady-state levels, whereas Siah-1 expression facilitates
HIPK2
polyubiquitination, degradation and thereby inactivation. During recovery from sublethal DNA damage,
HIPK2
, which is stabilized on DNA damage, is degraded through a Siah-1-dependent,
p53
-controlled pathway. Downregulation of Siah-1 inhibits
HIPK2
degradation and recovery from damage, driving the cells into apoptosis. We have also demonstrated that DNA damage triggers disruption of the
HIPK2
-Siah-1 complex, resulting in
HIPK2
stabilization and activation. Disruption of the
HIPK2
-Siah-1 complex is mediated by the ATM/ATR pathway and involves ATM/ATR-dependent phosphorylation of Siah-1 at Ser 19. Our results provide a molecular framework for
HIPK2
regulation in unstressed and damaged cells.
...
PMID:Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint kinases ATM and ATR. 1853 14
PML, a nuclear protein, interacts with several transcription factors and their coactivators, such as
HIPK2
and p300, resulting in the activation of transcription. Although PML is thought to achieve transcription activation by stabilizing the transcription factor complex, little is known about the underlying molecular mechanism. To clarify the role of PML in transcription regulation, we purified the PML complex and identified Fbxo3 (Fbx3), Skp1, and Cullin1 as novel components of this complex. Fbx3 formed SCF(Fbx3) ubiquitin ligase and promoted the degradation of
HIPK2
and p300 by the ubiquitin-proteasome pathway. PML inhibited this degradation through a mechanism that unexpectedly did not involve inhibition of the ubiquitination of
HIPK2
. PML, Fbx3, and
HIPK2
synergistically activated
p53
-induced transcription. Our findings suggest that PML stabilizes the transcription factor complex by protecting
HIPK2
and p300 from SCF(Fbx3)-induced degradation until transcription is completed. In contrast, the leukemia-associated fusion PML-RARalpha induced the degradation of
HIPK2
. We discuss the roles of PML and PML-retinoic acid receptor alpha, as well as those of
HIPK2
and p300 ubiquitination, in transcriptional regulation and leukemogenesis.
...
PMID:PML activates transcription by protecting HIPK2 and p300 from SCFFbx3-mediated degradation. 1880 79
The maintenance of
p53
transactivation activity is important for
p53
apoptotic function. We have shown that stable knockdown of
HIPK2
induces
p53
misfolding with inhibition of p53 target gene transcription. In this study we established a lentiviral-based system for doxycyclin (Dox)-induced conditional interference of
HIPK2
expression to evaluate the molecular mechanisms involved in
p53
deregulation. We found that
HIPK2
knockdown induced metallothionein 2A (MT2A) upregulation as assessed by RT-PCR analysis, increased promoter acetylation, and increased promoter luciferase activity. The MT2A upregulation correlated with resistance to Adriamycin (ADR)-driven apoptosis and with
p53
inhibition. Thus, acute knockdown of
HIPK2
(HIPK2i) induced misfolded
p53 protein
in MCF7 breast cancer cells and inhibited
p53
DNA-binding and transcription activities in response to ADR treatment. Previous works show that MT may modulate
p53
activity through zinc exchange. Here, we found that inhibition of MT2A expression by siRNA in the HIPK2i cells restored
p53
transcription activity. Similarly zinc supplementation to HIPK2i cells restored
p53
transcription activity and drug-induced apoptosis. These data support the notion that MT2A is involved in
p53
deregulation and strengthen the possibility that combination of chemotherapy and zinc might be useful to treat tumors with inactive wtp53.
...
PMID:Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc. 1899 71
HIPK2
is a eukaryotic Serine-Threonine kinase that controls cellular proliferation and survival in response to exogenous signals. Here, we show that the human transcription factor ZBTB4 is a new target of
HIPK2
. The two proteins interact in vitro, colocalize and associate in vivo, and
HIPK2
phosphorylates several conserved residues of ZBTB4. Overexpressing
HIPK2
causes the degradation of ZBTB4, whereas overexpressing a kinase-deficient mutant of
HIPK2
has no effect. The chemical activation of
HIPK2
also decreases the amount of ZBTB4 in cells. Conversely, the inhibition of
HIPK2
by drugs or by RNA interference causes a large increase in ZBTB4 levels. This negative regulation of ZBTB4 by
HIPK2
occurs under normal conditions of cell growth. In addition, the degradation is increased by DNA damage. These findings have two consequences. First, we have recently shown that ZBTB4 inhibits the transcription of p21. Therefore, the activation of p21 by
HIPK2
is two-pronged: stimulation of the activator
p53
, and simultaneous repression of the inhibitor ZBTB4. Second, ZBTB4 is also known to bind methylated DNA and repress methylated sequences. Consequently, our findings raise the possibility that
HIPK2
might influence the epigenetic regulation of gene expression at loci that remain to be identified.
...
PMID:The human protein kinase HIPK2 phosphorylates and downregulates the methyl-binding transcription factor ZBTB4. 1944 68
Our previous studies have implicated CHIP (carboxyl terminus of Hsp70-interacting protein) as a co-chaperone/ubiquitin ligase whose activities yield protection against stress-induced apoptotic events. In this report, we demonstrate a stress-dependent interaction between CHIP and Daxx (death domain-associated protein). This interaction interferes with the stress-dependent association of
HIPK2
with Daxx, blocking phosphorylation of serine 46 in
p53
and inhibiting the
p53
-dependent apoptotic program. Microarray analysis confirmed suppression of the
p53
-dependent transcriptional portrait in CHIP(+/+) but not in CHIP(-/-) heat shocked mouse embryonic fibroblasts. The interaction between CHIP and Daxx results in ubiquitination of Daxx, which is then partitioned to an insoluble compartment of the cell. In vitro ubiquitination of Daxx by CHIP revealed that ubiquitin chain formation utilizes non-canonical lysine linkages associated with resistance to proteasomal degradation. The ubiquitination of Daxx by CHIP utilizes lysines 630 and 631 and competes with the sumoylation machinery of the cell at these residues. These studies implicate CHIP as a stress-dependent regulator of Daxx that counters the pro-apoptotic influence of Daxx in the cell. By abrogating
p53
-dependent apoptotic pathways and by ubiquitination competitive with Daxx sumoylation, CHIP integrates the proteotoxic stress response of the cell with cell cycle pathways that influence cell survival.
...
PMID:Stress-dependent Daxx-CHIP interaction suppresses the p53 apoptotic program. 1946 79
In the past few years, much effort has been devoted to show the single-target specificity of nongenotoxic,
p53
reactivating compounds. However, the divergent biological responses induced by the different compounds, even in the same tumor cells, demand additional mechanistic insights, whose knowledge may lead to improved drug design or selection of the most potent drug combinations. To address the molecular mechanism underlying induction of mitotic arrest versus clinically more desirable apoptosis, we took advantage of two MDM2 antagonists, Nutlin-3 and RITA, which respectively produce these two outcomes. We show that, along with
p53
reactivation, the proapoptotic
p53
-activator
HIPK2
is degraded by MDM2 in Nutlin-3-treated cells, but activated by transiently reduced MDM2 levels in RITA-treated ones. Gain- and loss-of-function experiments revealed the functional significance of MDM2-mediated
HIPK2
regulation in cell decision between mitotic arrest and apoptosis in both types of
p53
reactivation. These data indicate that strategies of
p53
reactivation by MDM2 inhibition should also take into consideration MDM2 targets other than
p53
, such as the apoptosis activator
HIPK2
.
...
PMID:HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA. 1963 86
<< Previous
1
2
3
4
5
Next >>